|
|
|
|
|
Botulinum toxin type B
drug data and news
Botulinum toxin type B drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Botulinum toxin type B | ||
| Brand Names/Synonyms | Botulinum neurotoxin type A precursor;BoNT/A;Bontoxilysin A;BOTOX[Contains: Botulinum neurotoxin A light- chain; Botulinum neurotoxin A heavy-chain]; Myobloc (Elan Corp; Solstice Neurosciences) | ||
| Indication | For treatment of cervical dystonia, axillary hyperhidrosis, strabismus, facial wrinkles | ||
| Sponsored links | Description | Neurotoxin produced by fermentation of clostridium botulinum type B. The protein exists in noncovalent association with hemagglutinin and nonhemagglutinin proteins as a neurotoxin complex. The neurotoxin complex is recovered from the fermentation process and purified through a series of precipitation and chromatography steps. | |
| Pharmacology | Myobloc inhibits acetylcholine release at the neuromuscular junction via a three stage process: 1) Heavy Chain mediated neurospecific binding of the toxin, 2) internalization of the toxin by receptor-mediated endocytosis, and 3) ATP and pH dependent translocation of the Light Chain to the neuronal cytosol where it acts as a zinc-dependent endoprotease cleaving polypeptides essential for neurotransmitter release. | ||
| Mechanism Of Action | Myobloc binds to and cleaves the synaptic Vesicle Associated Membrane Protein (VAMP, also known as synaptobrevin) which is a component of the protein complex responsible for docking and fusion of the synaptic vesicle to the presynaptic membrane, a necessary step to neurotransmitter release. | ||
| Botulinum toxin type B News (When available) |
APS: For Migraine and Cluster Headaches, Most Anything Is Worth a ... May 15, 2006 Noridian Part B Carrier Grants a Single Coverage Policy for ... May 1, 2006 PainCare Holdings and Solstice Neurosciences, Inc. Announce a ... May 10, 2006 PainCare Collaborates With Solstice Neurosciences For Treatment Of ... May 10, 2006 (PRN) - UNICCO Service Company Announces Resolution of Labor ... May 1, 2006 Solstice says study data confirms comparable clinical profiles of ... May 1, 2006 | ||
| Dosage Forms | SOLUTION | ||
| Drug_Category | Antidystonic Agents; Anti-Wrinkle Agents; serums (80:04.00) | ||
| Absorption | Not Available | ||
| Interactions | Not Available | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | Clostridium botulinum toxin type B | ||
| Chemical Formula | C6760H10447N1743O2010S32 | ||
| Molecular Weight | 149322.7 | ||
| Smiles String | Not Available | ||
| Melting Point | Not Available | ||
| Water Solubility | Not Available | ||
| State | Transparent, slightly viscous, aqueous liquid | ||
| LogP/Hphobicity | -0.368 | ||
| Isoelectric Point | 6.06 | ||
| Biotransformation | Not Available | ||
| Half Life | Not Available | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Botulinum_toxin_type_B.html http://www.rxlist.com/cgi/generic2/botulinumtoxin.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | BIOD00070 | ||
| CAS Registry Number | Not Available | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | Not Available | ||
| PharmGKB ID | PA448660 | ||
| SwissProt ID | BXA1_CLOBO (P10845) | ||
| GenBank ID | X52066 | ||
| Drug ID Number [DIN] | 75108 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |